References
- Keizcr HG, Pinedo HM, Schuurhuis GJ, Joenje H. Doxorubicin (Adriamycin): a critical review of free radicaldependent mechanisms of cytotoxicity. Pharmac Ther 1990; 47: 219–231.
- Powis G. Free radical formation by antitumor quinones. Free Rad Biol Med 1989; 6: 63–101.
- Crescimanno M, Armata MG, Florena AM et al. Antioxidant defenses in a B16 melanoma line resistant to doxorubicin: an in vivo study. Anti-Cancer Drugs 1991; 2: 481–486.
- Mazouzi Z, Francastel C, Tapiero H, Robert-Lezenes J. Growth inhibition of doxorubicin-resistant K562 leukemia cells by anthracyclines: absence of correlation with erythroid differentiation. J Cell Pharmacol 1991; 2: 157–164.
- Schisselbauer JC, Crescimanno M, D’Alessandro N et al. Glutathione, glutathione S-transferases, and related redox enzymes in adriamycin-resistant cell lines with a multidrug resistant phenotype. Cancer Commun 1989; 1: 133–139.
- Griffith OW. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinyl-piridine. Anal Biochem 1979; 106: 207–214.
- Lutzky J, Astor MB, Taub RN et al. Role of glutathione and dependent enzymes in anthracycline-resistant HL60/AR cells. Cancer Res 1989; 49: 4120–4125.
- Crescimanno M, D’Alessandro N, Armata MG, Toulmond S, Tapiero H. Modulation of the antioxidant activities in Dox-sensitive and -resistant Friend leukemia cells. Effect of Doxorubicin. Anticancer Res 1991; 11: 901–903.
- Kramer RA, Zakher J, Kim G. Role of the glutathione redox cycle in acquired and de novo multidrug resistance. Science 1988; 241: 694–697.
- Hamilton TC, Winker MA, Louie KG et al. Augmentation of adriamycin, melphalan and cisplatin cytotoxicity in drug- resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 1985; 34: 2583–2586.
- Lee FY, Sciandra J, Siemann DW. A study of the mechanism of resistance to adriamycin in vivo. Glutathione metabolism, P-glycoprotein, and drug transport. Biochem Pharmacol 1989; 38: 3697–3705.
- Sinha BK, Mimnaugh EG, Rajagopalan S, Myers CE. Adriamycin activation and oxygen free radical formation in human breast tumor cells: protective role of glutathione peroxidase in adriamycin resistance. Cancer Res 1989; 49: 3844–3848.
- Luduena RF, Roach MC. Tubulin sulfhydryl groups as probes and targets for antimitotic and antimicrotubule agents. Pharmac Ther 1991; 49: 133–152.
- Rosenberg MC, Colvin OM, Griffith OW et al. Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross- resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion. Cancer Res 1989; 49: 6917–6922.
- Neumann M, Wilish A, Diddens H, Probst H, Gekeler V. MDR hamster cells exhibiting multiple altered gene expression: effects of dexniguldipine-HCl (B859-35), cyclosporin A and buthionine sulfoximine. Anticancer Res 1992; 12: 2297–2302.
- Liebman JE, Hahn SM, Cook JA, Lipschultz C, Mitchell JB, Kaufman DC. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity. Cancer Res 1993; 53: 2066–2070.
- Maeda O, Terasawa M, Ishikawa T et al. A newly synthesized bifunctional inhibitor, W-77, enhances adriamycin activity against human ovarian carcinoma cells. Cancer Res 1993; 53: 2051–2056.